Xencor, Inc. reported total revenues of $32.732 million for the first quarter of 2025, a significant increase from $15.997 million in the same period last year. The company's net loss attributable to Xencor, Inc. decreased to $48.418 million from $73.440 million year-over-year, driven by higher revenues and lower other expenses, despite an increase in operating expenses.

Xencor's total revenue for Q4 2024 was $52.8 million, a slight increase from $51.0 million in Q4 2023. The company reported a net loss of $46.2 million for the quarter, compared to a net loss of $26.3 million in the same period last year. The diluted EPS for Q4 2024 was -$0.62.

Xencor reported Q3 2024 financial results, including revenues of $10.7 million and a net loss of $45.1 million. The company highlighted progress in its clinical pipeline, particularly in oncology and autoimmune programs, and announced Amgen's advancement of xaluritamig into Phase 3 development. Xencor's cash, cash equivalents, and marketable debt securities totaled $754.3 million as of September 30, 2024.

Xencor reported revenues of $17.0 million and a net loss of $66.0 million for the second quarter ended June 30, 2024. The company's cash, cash equivalents, and marketable debt securities totaled $585.0 million as of June 30, 2024. They expect to end 2024 with between $475 million and $525 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2027.

Xencor reported a net loss of $68.0 million, or $(1.11) per share, for the first quarter ended March 31, 2024. Revenues for the quarter were $12.8 million, compared to $19.0 million for the same period in 2023. Cash, cash equivalents and marketable debt securities totaled $646.7 million as of March 31, 2024.

Xencor reported Q4 2023 financial results, highlighting progress in clinical development with XmAb T cell engagers and vudalimab. The company's financial position was strengthened by royalty monetization and milestone payments, exceeding $325 million in proceeds. Early clinical data for vudalimab monotherapy in high-risk mCRPC patients showed promising results.

Xencor reported third-quarter financial results, highlighting a $215 million upfront payment from a royalty transaction with OMERS Life Sciences. The company is focusing on targeted T cell-engaging bispecifics and has made pipeline decisions to extend its cash runway into 2027.

Xencor reported a total revenue of $45.5 million for the second quarter of 2023, compared to $30.2 million for the same period in 2022. The net loss for the quarter was $22.0 million, or $(0.37) per share, compared to a net loss of $34.0 million, or $(0.57) per share, for the same period in 2022.

Xencor reported a net loss of $60.8 million, or $(1.02) per share, for the first quarter ended March 31, 2023. Revenues were $19.0 million, compared to $85.5 million for the same period in 2022. Cash, cash equivalents, receivables and marketable debt securities totaled $568.2 million as of March 31, 2023.

Xencor reported a net loss of $12.0 million for the fourth quarter of 2022, compared to a net income of $73.1 million for the same period in 2021. Total revenue for the fourth quarter was $21.6 million, compared to $154.0 million for the same period in 2021. The company's cash, cash equivalents, receivables, and marketable debt securities totaled $613.5 million as of December 31, 2022.

Xencor reported Q3 2022 financial results, with total revenue of $27.3 million and a net loss of $32.8 million, or $(0.55) per share. The company's cash, cash equivalents, receivables, and marketable debt securities totaled $654.6 million as of September 30, 2022. Xencor also announced initial results from its Phase 1a study of XmAb564, which showed promising tolerability and T-cell expansion.